1. Home
  2. CPAY vs GMAB Comparison

CPAY vs GMAB Comparison

Compare CPAY & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corpay Inc.

CPAY

Corpay Inc.

HOLD

Current Price

$314.71

Market Cap

22.0B

Sector

Technology

ML Signal

HOLD

Logo Genmab A/S ADS

GMAB

Genmab A/S ADS

HOLD

Current Price

$32.50

Market Cap

21.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPAY
GMAB
Founded
1986
1999
Country
United States
Denmark
Employees
11200
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.0B
21.1B
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
CPAY
GMAB
Price
$314.71
$32.50
Analyst Decision
Buy
Strong Buy
Analyst Count
11
6
Target Price
$369.36
$40.00
AVG Volume (30 Days)
500.0K
2.0M
Earning Date
02-04-2026
02-17-2026
Dividend Yield
N/A
N/A
EPS Growth
5.04
132.41
EPS
14.72
25.10
Revenue
$4,314,608,000.00
$3,845,670,022.00
Revenue This Year
$15.86
$24.85
Revenue Next Year
$15.70
$16.51
P/E Ratio
$21.38
$12.51
Revenue Growth
11.27
29.57
52 Week Low
$252.84
$17.24
52 Week High
$400.81
$35.43

Technical Indicators

Market Signals
Indicator
CPAY
GMAB
Relative Strength Index (RSI) 48.58 48.15
Support Level $314.67 $32.57
Resistance Level $322.45 $33.38
Average True Range (ATR) 8.78 0.97
MACD -1.52 -0.12
Stochastic Oscillator 34.45 37.36

Price Performance

Historical Comparison
CPAY
GMAB

About CPAY Corpay Inc.

Corpay Inc is a corporate payments company that helps businesses and consumers manage and pay their expenses. Its suite of modern payment solutions helps customers manage vehicle-related expenses, lodging expenses, and corporate payments. Its reportable segments are; Vehicle Payments, Corporate Payments, Lodging Payments, and Other. The group's geographic areas are the United States, Brazil, the United Kingdom, and Other.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: